

nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

Lauren E. Dockery, MD, MS¹; Brian Slomovitz, MD²; Anna Priebe, MD³; Angela K. Green, MD⁴; Cara Mathews, MD⁵; Fernanda Musa, MD⁵; Fernanda Musa

¹Stephenson Cancer Center, Oklahoma University Health, Oklahoma City, OK; ²Mount Sinai Medical Center, New York, NY; ⁵Women & Infants Hospital, Providence, RI; ⁶Swedish Cancer Institute, Seattle, WA; ⁷Atrium Health Levine Cancer Institute, Charlotte, NC; ⁸University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Sciences, Little Rock, AR; ⁹Women's Cancer Center of Nevada, Las Vegas, NV; ¹⁰Aadi Bioscience, Pacific Palisades, CA

Objective

This trial is designed to evaluate the safety and efficacy of *nab*-sirolimus in combination with letrozole for the treatment of patients with advanced or recurrent endometrioid endometrial carcinoma who have received 0–1 prior lines of chemotherapy in the recurrent/advanced setting

KEY POINTS



Dysregulation of the mTOR pathway has been demonstrated in most endometrial carcinomas and crosstalk between the mTOR pathway and the ER signaling pathway has been implicated in resistance to endocrine therapy



Consistent with this, the combination of mTOR inhibitors and endocrine therapy has shown clinical activity in patients with advanced or recurrent endometrial carcinoma



nab-Sirolimus is an mTOR inhibitor that demonstrated improved tumor accumulation, better mTOR suppression, and enhanced antitumor activity compared with oral mTOR inhibitors in animal models



This phase 2, open-label, single-arm, multicenter study (NCT05997017) is evaluating *nab*-sirolimus in combination with letrozole for the treatment of patients with advanced or recurrent EEC, and is currently open for enrollment

SGO Annual Meeting on Women's Cancer; San Diego, CA; March 16–18, 2024

Correspondence: MedInfo@AadiBio.com

INTRODUCTION

- patients with advanced or recurrent endometrial carcinoma (EC) remain necessary
- Dysregulation of mTOR signaling is implicated in the pathology of EC, particularly in endometrioid EC (EEC) in which >80% harbor PTEN or PI3K/AKT/mTOR pathway alterations²
- PTEN normally acts to reverse the activity of PI3K, and therefore inhibits activation of the pathway. Low PTEN expression can lead to overactivation of the PI3K/AKT/mTOR pathway³
- Moreover. crosstalk between the PI3K/AKT/mTOR pathway and estrogen signaling occurs at several points in the pathway^{3,4} (**Figure 1**), including:
- Direct activation of the PI3K/AKT/mTOR pathway via activated ERs
- Direct activation of ERs via the downstream signaling molecule S6K
- ER induced expression of S6K in a feed-forward activation loop⁴
- Potentiation of ER signaling can lead to the development of resistance to endocrine therapy;⁴ thus, combining therapies is an attractive strategy to overcome potential resistance
- GOG-3007⁵ and other phase 2 studies^{6,7} have demonstrated that the combination of oral mTOR inhibitors and endocrine therapy provides clinical benefit in patients with recurrent EC. This benefit was particularly pronounced in chemotherapy-naïve patients⁵
- In the GOG-3007 study of everolimus plus letrozole, the median PFS was 28 months in chemotherapy-naïve patients versus 4 months for patients with prior chemotherapy⁵
- All patients who benefited from the combined therapy had tumors with endometrioid histology⁵

Acknowledgements & Disclosures

This study was supported by Aadi Bioscience. For disclosures of co-authors please see abstract.


• THE POWER OF SHARED PURPOSE: Transforming Gynecologic Cancer Care

Despite recent data demonstrating improved outcomes with immunotherapy plus chemotherapy, regardless of mismatch repair status,¹ alternative treatment options for

1. Crosstalk between ERs and the **PI3K/AKT/mTOR pathway.**

(1) Activated ERs directly bind PI3K leading to its sphorylation and subsequent activation of the pathway (2) S6K phosphorylates and activates ERs, leading to expression of receptor ligands, S6K, receptor tyrosine kinases and signaling adaptors, which result in upstream activation of the pathway.

(3) Estrogen bound ERs recruit Raptor to the nucleus and promote expression of growth factors, which in turn activate the pathway.



- nab-Sirolimus is a nanoparticle albumin-bound, IV administered mTOR inhibitor approved in the United States for adults with advanced malignant perivascular epithelioid cell tumor (PEComa)⁸
- Nonclinical data with *nab*-sirolimus demonstrated improved tumor accumulation, mTOR inhibition, and tumor growth suppression compared with oral mTOR inhibitors⁹
- We hypothesize that *nab*-sirolimus in combination with letrozole may produce synergistic antitumor activity in patients with EEC

STUDY DESIGN

advanced or recurrent EEC (Figure 2)


2. Study design

N = up to 29 patie

- Adult patients with metastatic or locally surgical resection is not an option
- mTOR inhibitor-naïve
- ECOG PS 0 or 1
- ≥1 measurable target lesion at baseline

Treatme

- nab-Sirolimus 100 mg/m² administered 30 minutes on days 1 and 8 of each 21-d Starting dose of 100 mg/m² may be r
- patients have a dose reduction withi
- Maximum of 3 sequential dose reduc 45 mg/m² are permitted for manage
- Letrozole 2.5 mg administered orally, dai



Decisions related to treatment (e.g., discontinuation, change of treatment, dose reduction) will be at the discretion of the investigator NCT05997017

AEs, adverse events; CT, computerized tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; EEC, endometrioid endometrial carcinoma; MRI, magnetic resonance imaging; RECIST, Response Evaluation Criteria in Solid Tumors

References

- 2. Mutter GL, et al. J Natl Cancer Inst. 2000;92:924–930.
- 3. Driva TS, et al. *Int J Mol Sci*. 2022;23:3416.

Medical writing and editorial assistance were provided by Oishika Panda, PhD, CMPP and Andrea Humphries, PhD, CMPP, of Twist Medical, and were funded by Aadi Bioscience.

Dr. Lauren Dockery reports that she has served on an advisory board for Aadi Bioscience and received a consulting fee.

This is a phase 2, open-label, single-arm, multicenter study, evaluating *nab*-sirolimus in adult patients (≥18 years) with

Key eligibility criteria	
ents – Adjuv inhibi was c v advanced EEC where – Recur prior comp – Nonc	or therapy allowed: cant setting – chemotherapy, hormonal therapy, checkpoint tors, and/or other therapy, as long as the adjuvant therapy ompleted ≥6 months prior to enrollment rent/advanced/metastatic setting – treatment with 0–1 chemotherapy regimens; chemotherapy must have been leted ≥3 months prior to enrollment memotherapy-based treatment as long as therapy ended teeks prior to enrollment
nt phase	Follow-up
nt phase as an intravenous infusion over day cycle reduced to 75 mg/m ² , if 3/6 or 4/10 in the first 4 months actions to 75 mg/m ² , 56 mg/m ² , and ement of AEs aily	 Follow-up CT/MRI every 6 weeks for the first year and every 12 weeks thereafter, until disease progression Safety is continuously monitored; AEs are collected throughout treatment Quarterly follow-up until study closure, death, or consent withdrawal

Repeat until disease progression, unacceptable toxicity, withdrawal of consent, or at investigator discretion

- Patients with advanced or recurrent EEC who are chemotherapy-naïve or who have received one line of chemotherapy in the recurrent, advanced, or metastatic setting are eligible
- Patients who received prior therapy in the recurrent, advanced, or metastatic setting must have attained at least a partial response
- Prior adjuvant therapy is permitted as long as it was completed at least 6 months prior to enrollment
- Nonchemotherapy-based treatment is permitted at any point as long as therapy ended at least 4 weeks prior to enrollment
- Using a Simon's optimal 2-stage design, the study will enroll 10 patients in stage 1. If one patient achieves a response, stage 2 will enroll 19 patients

Study Endpoints

recurrent EEC (Figure 3)

3. Study endpoints



^aDefined as the proportion of patients who achieved a confirmed PR or CR from the time of study treatment initiation until end of study treatment. ^bDOR defined as the time from first PR/CR to disease progression or death; DCR defined as the proportion of patients with confirmed PR/CR or stable disease for \geq 12 weeks; time to response defined as the time from the first dose of study medication to confirmed PR/CR; PFS defined as the number of months from treatment initiation to disease progression or death due to any cause; OS defined as the number of months from treatment initiation to death. ^cAEs defined per the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. AE, adverse event; CR, complete response; DCR, disease control rate; DOR, duration of response; IHC, immunohistochemistry; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria for Solid Tumors.

Trial enrollment information

- Trial registration: NCT05997017
- Study start date: December 2023
- Current status: Open for enrollment in the United States
- Texas Oncology Tyler, Tyler, Texas; Swedish Cancer Institute, Seattle, Washington

1. Eskander RN, et al. *N Engl J Med*. 2023;388:2159–2170. 4. Alayev A, et al. *Oncogene*. 2016;35:3535–3543.

- 5. Slomovitz BM, et al. *Gynecol Oncol*. 2022;164:481–491.
- 6. Slomovitz BM, et al. J Clin Oncol. 2015;33:930–936 7. Soliman PT, et al. *Clin Cancer Res*. 2020;26:581–587.
- FYARRO[®] (sirolimus protein-bound particles for injectable suspension [albumin-bound]). Package insert. Aadi Bioscience, Inc., Pacific Palisades, CA; December 2021.
- 9. Hou S, et al. Cancer Res. 2019;79(13 Supplement):348.



• The primary objective of the study is to determine the proportion of patients with a best overall response rate of a confirmed complete or partial response to *nab*-sirolimus in combination with letrozole in patients with advanced or

S E C O N D A R Y

DOR, DCR, time to response, PFS, OS,^b



EXPLORATORY

Baseline molecular biomarkers and genomics; association between molecular/genomic profile and clinical outcome using NGS and IHC

 Current study locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida; Women's Cancer Center of Nevada, Las Vegas, Nevada; Oklahoma University Stephenson Cancer Center, Oklahoma City, Oklahoma; Women & Infants Hospital, Providence, Rhode Island;

> Copies of this poster obtained thro Quick Response (QR) Code are for perso use only and may not be reproduced with permission from the author of this post

